Evidence map›Paper›PMID 19309415›Full record

Trial reportNeurogastroenterology and motility2009

Pharmacogenetics of low dose clonidine in irritable bowel syndrome.

M Camilleri, I Busciglio, P Carlson, S McKinzie, D Burton, K Baxter, M Ryks, A R Zinsmeister

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Neurogastroenterology and motility, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Effects of clonidine in women with fecal incontinence.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2014
    Trial
  3. Irritable Bowel Syndrome Clinical Care Gaps and the Potential of Future Therapeutics Based on Peripheral Visceral Afferent Modulation.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026
    Review
  4. Review
  5. G protein beta 3(Oncotarget · 2018
    Article
  6. Review
  7. Review
  8. Article
  9. Cannabinoid receptor 1 gene and irritable bowel syndrome: phenotype and quantitative traits.American journal of physiology. Gastrointestinal and liver physiology · 2013
    Article
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

M CamilleriClinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, MN 55905, USA. camilleri.michael@mayo.edu
I Busciglio
P Carlson
S McKinzie
D Burton
K Baxter
M Ryks
A R Zinsmeister
Mayo Clinic in Florida · USMayo Clinic · US

Funding

ALPHA 2 ADRENERGIC CONTROL OF COLONIC FUNCTION IN IBSR01DK054681 · NIDDK · MAYO CLINIC ROCHESTER · PI CAMILLERI, MICHAEL L · 1999 to 2007
$1.5M
ALPHA 2 ADRENERGIC CONTROL IN IRRITABLE BOWEL SYNDROMEK24DK002638 · NIDDK · MAYO CLINIC ROCHESTER · PI CAMILLERI, MICHAEL L. · 1999 to 2008
$1.1M
NIDDK NIH HHS K24 DK002638NIDDK NIH HHS K24 DK-02638NIDDK NIH HHS R01 DK054681NIDDK NIH HHS R01 DK-54681
6 · The paper itself

Abstract

Adrenergic and serotonergic (ADR-SER) mechanisms alter gut (gastrointestinal, GI) sensorimotor functions. We aimed to determine whether candidate ADR-SER genes affect GI responses to low dose clonidine (CLO) in humans. Forty healthy and 120 irritable bowel syndrome (IBS) participants received CLO, 0.1 mg or 0.15 mg b.i.d., for 6 days. At baseline and post-CLO, we measured: gastric volume (GV); satiation volume; rectal compliance, sensation thresholds and ratings with distensions. Genetic variations tested were: alpha2A (C-1291G), alpha2C (Del 322-325), GNbeta3 (C825T) and solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 (SLC6A4) (serotonin transporter linked polymorphic region). CLO reduced volume to satiation (P = 0.002), postprandial GV (P < 0.001), sensation threshold for pain (<0.001); CLO increased rectal compliance (P = 0.024). There were significant associations between post-CLO responses and gene variations for DeltaGV (alpha2A and SLC6A4), rectal sensation of gas (alpha2A, GNbeta3), urgency (alpha2A); and pain (GNbeta3 and SLC6A4); and rectal compliance (SLC6A4). alpha2A, GNbeta3 and SLC6A4 genotypes significantly modify responses to CLO on sensory and motor GI functions in health and IBS.

Indexed as

Adrenergic alpha-AgonistsClonidineDose-Response Relationship, DrugFemaleHeterotrimeric GTP-Binding ProteinsHumansIrritable Bowel SyndromeMalePharmacogeneticsPolymorphism, Single NucleotideReceptors, Adrenergic, alpha-2Serotonin Plasma Membrane Transport ProteinsAdrenergic alpha-AgonistsClonidineG-protein beta3 subunitHeterotrimeric GTP-Binding ProteinsReceptors, Adrenergic, alpha-2Serotonin Plasma Membrane Transport ProteinsSLC6A4 protein, human

Identifiers

PMID19309415
PMCPMC2690641
OpenAlexW2057215387

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.